Relief Therapeutics Holding SA (SWX: RLF)
Market Cap | 19.50M |
Revenue (ttm) | 8.60M |
Net Income (ttm) | -46.24M |
Shares Out | 12.54M |
EPS (ttm) | -3.70 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 59,231 |
Open | 1.550 |
Previous Close | 1.555 |
Day's Range | 1.550 - 1.820 |
52-Week Range | 1.055 - 4.200 |
Beta | -14.74 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Sep 17, 2024 |
About RLF
Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting; OLPRUVA, a sodium phenylbutyrate for the treatment of urea cycle disor... [Read more]
Financial Performance
In 2023, STRN's revenue was 128.57 million, an increase of 16.41% compared to the previous year's 110.45 million. Earnings were 5.89 million, an increase of 71.74%.
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/t/q/press10-2620240.jpg)
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
GENEVA, SWITZERLAND / ACCESSWIRE / September 2, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...
Relief Therapeutics reports 1H results
![](https://cdn.snapi.dev/images/v1/t/a/press20-2617376.jpg)
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025 Streamlined ope...
![](https://cdn.snapi.dev/images/v1/s/d/press20-2566654.jpg)
Relief Therapeutics Secures up to $11 Million from Royalty Sales
Non-dilutive funding to support RLF-TD011 clinical development and pipeline advancement GENEVA, SWITZERLAND / ACCESSWIRE / August 5, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:...
![](https://cdn.snapi.dev/images/v1/j/j/press11-2499283.jpg)
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
GENEVA, SWITZERLAND / ACCESSWIRE / June 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to de...
![](https://cdn.snapi.dev/images/v1/i/t/press15-2458247.jpg)
Relief Therapeutics Announces Executive Changes
GENEVA, SWITZERLAND / ACCESSWIRE / June 3, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to del...
![](https://cdn.snapi.dev/images/v1/i/x/press4-2417152.jpg)
Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innova...
![](https://cdn.snapi.dev/images/v1/c/9/press5-2398845.jpg)
Relief Therapeutics has Published its Annual Report
GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief), a biopharmaceutical company committed to delivering innovative treatmen...
![](https://cdn.snapi.dev/images/v1/t/n/press6-2394636.jpg)
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESSWIRE / April 26, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF, RLFTY) (Relief Therapeutics, or the C...
![](https://cdn.snapi.dev/images/v1/d/g/press13-2343205.jpg)
RELIEF THERAPEUTICS Holding SA to Hold Extraordinary General Meeting
Relief Therapeutics Calls Extraordinary General Meeting Anticipated Board of Directors Overhaul GENEVA, SWITZERLAND / ACCESSWIRE / March 27, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF...
![](https://cdn.snapi.dev/images/v1/p/r/press18-2337237.jpg)
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
![](https://cdn.snapi.dev/images/v1/0/p/press16-2297654.jpg)
Relief Therapeutics Renews CHF 50 million Share Subscription Facility
3-year CHF 50 million capital commitment from GEM Relief advances strategic transformation GENEVA, SWITZERLAND / ACCESSWIRE / February 28, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(...
![](https://cdn.snapi.dev/images/v1/p/6/press9-2183020.jpg)
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
GENEVA, SWITZERLAND / ACCESSWIRE / December 5, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i...
![](https://cdn.snapi.dev/images/v1/x/f/press6-2168309.jpg)
Relief Therapeutics Announces CEO Transition
GENEVA, SWITZERLAND / ACCESSWIRE / November 22, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering ...
![](https://cdn.snapi.dev/images/v1/2/m/press5-2096100.jpg)
Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering i...
![](https://cdn.snapi.dev/images/v1/n/c/press20-2064790.jpg)
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
GENEVA, SWITZERLAND / ACCESSWIRE / September 15, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering...
![](https://cdn.snapi.dev/images/v1/3/7/conf11-2046227.jpg)
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
GENEVA, SWITZERLAND / ACCESSWIRE / September 1, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering inn...
![](https://cdn.snapi.dev/images/v1/m/s/press6-2044020.jpg)
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA™ worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with the potential fo...
![](https://cdn.snapi.dev/images/v1/b/q/press1-1977245.jpg)
Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Recent Pentech Health acquisition of ZOIA Pharma broadens distribution and access for patients to PKU GOLIKE® GENEVA, SWITZERLAND / ACCESSWIRE / July 19, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF...
![](https://cdn.snapi.dev/images/v1/x/m/press14-1939761.jpg)
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
GENEVA, SWITZERLAND / ACCESSWIRE / June 20, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to de...
![](https://cdn.snapi.dev/images/v1/q/g/press14-1867539.jpg)
Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
GENEVA, SWITZERLAND / ACCESSWIRE / May 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics), a biopharmaceutical company committed to delivering innovativ...
![](https://cdn.snapi.dev/images/v1/7/e/press2-1862467.jpg)
Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
Acer reports OLPRUVA™ drug availability anticipated in mid-June 2023; Acer is engaged in discussions with payers representing a substantial majority of covered lives; 70 percent of metabolic treatment...
![](https://cdn.snapi.dev/images/v1/r/m/press7-1861248.jpg)
Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Shareholders approved all proposals by a large majority; Company to effectuate consolidation of ordinary shares in advance of planned Nasdaq Stock Market dual listing; ADR program will be terminated u...
![](https://cdn.snapi.dev/images/v1/e/2/press5-1838949.jpg)
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100 ® (Aviptadil Acetate) Relief to file a revised provisional patent application for RLF...
![](https://cdn.snapi.dev/images/v1/d/n/press19-1837090.jpg)
Relief Therapeutics Announces Full Year 2022 Financial Results and Provides Corporate Update
GENEVA, SWITZERLAND / ACCESSWIRE / April 3, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief Therapeutics, or Relief), a biopharmaceutical company committed to deliver...